» Articles » PMID: 20458040

Phase I Dose-escalation Study of Recombinant Human Apo2L/TRAIL, a Dual Proapoptotic Receptor Agonist, in Patients with Advanced Cancer

Overview
Journal J Clin Oncol
Specialty Oncology
Date 2010 May 12
PMID 20458040
Citations 214
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Apoptosis ligand 2/tumor necrosis factor-related apoptosis-inducing ligand (Apo2L/TRAIL)-a member of the tumor necrosis factor cytokine family-induces apoptosis by activating the extrinsic pathway through the proapoptotic death receptors DR4 and DR5. Recombinant human Apo2L/TRAIL (rhApo2L/TRAIL) has broad potential as a cancer therapy. To the best of our knowledge, this is the first in-human clinical trial to assess the safety, tolerability, pharmacokinetics, and antitumor activity of multiple intravenous doses of rhApo2L/TRAIL in patients with advanced cancer.

Patients And Methods: This phase I, open-label, dose-escalation study treated patients with advanced cancer with rhApo2L/TRAIL doses ranging from 0.5 to 30 mg/kg/d, with parallel dose escalation for patients without liver metastases and with normal liver function (cohort 1) and for patients with liver metastases and normal or mildly abnormal liver function (cohort 2). Doses were given daily for 5 days, with cycles repeating every 3 weeks. Assessments included adverse events (AEs), laboratory tests, pharmacokinetics, and imaging to evaluate antitumor activity.

Results: Seventy-one patients received a mean of 18.3 doses; seven patients completed all eight treatment cycles. The AE profile of rhApo2L/TRAIL was similar in cohorts 1 and 2. The most common AEs were fatigue (38%), nausea (28%), vomiting (23%), fever (23%), anemia (18%), and constipation (18%). Liver enzyme elevations were concurrent with progressive metastatic liver disease. Two patients with sarcoma (synovial and undifferentiated) experienced serious AEs associated with rapid tumor necrosis. Two patients with chondrosarcoma experienced durable partial responses to rhApo2L/TRAIL.

Conclusion: At the tested schedule and dose range, rhApo2L/TRAIL was safe and well tolerated. Dose escalation achieved peak rhApo2L/TRAIL serum concentrations equivalent to those associated with preclinical antitumor efficacy.

Citing Articles

Turn TRAIL Into Better Anticancer Therapeutic Through TRAIL Fusion Proteins.

Wang Y, Qian X, Wang Y, Yu C, Feng L, Zheng X Cancer Med. 2024; 14(1):e70517.

PMID: 39740038 PMC: 11683677. DOI: 10.1002/cam4.70517.


Unlocking the Secrets of Extracellular Vesicles: Orchestrating Tumor Microenvironment Dynamics in Metastasis, Drug Resistance, and Immune Evasion.

Mir R, Baba S, Elfaki I, Algehainy N, Alanazi M, Altemani F J Cancer. 2024; 15(19):6383-6415.

PMID: 39513123 PMC: 11540496. DOI: 10.7150/jca.98426.


Tumor necrosis factor superfamily signaling: life and death in cancer.

Ababneh O, Nishizaki D, Kato S, Kurzrock R Cancer Metastasis Rev. 2024; 43(4):1137-1163.

PMID: 39363128 PMC: 11554763. DOI: 10.1007/s10555-024-10206-6.


Combining gemcitabine and MSC delivering soluble TRAIL to target pancreatic adenocarcinoma and its stroma.

Grisendi G, DallOra M, Casari G, Spattini G, Farshchian M, Melandri A Cell Rep Med. 2024; 5(8):101685.

PMID: 39168103 PMC: 11384958. DOI: 10.1016/j.xcrm.2024.101685.


Using gene therapy to circumvent limitations of TRAIL-based cancer therapy.

Yin L Mol Ther Oncol. 2024; 32(3):200844.

PMID: 39104912 PMC: 11298915. DOI: 10.1016/j.omton.2024.200844.